Weight change at 12 and 24 months follow-up among patients with T2DM initiating GLP-1 RA therapy in the CPRD dataset
| 12-month follow-up | 24-month follow-up | |
| N=341 | N=232 | |
| n (%) | n (%) | |
| Any weight loss or maintain baseline weight | 242 (71.0) | 157 (67.7) |
| Weight loss ≥5% | 114 (33.4) | 101 (43.5) |
| Weight loss <5%* | 128 (37.5) | 56 (24.1) |
| Weight gain | 99 (29.0) | 75 (32.3) |
| 12-month follow-up | 24-month follow-up | |||||
| Weight loss ≥5% of baseline weight | <5% weight loss† | Overall | Weight loss ≥5% of baseline weight | <5% weight loss† | Overall | |
| Mean (SD) weight change, kg | −13.7 (8.6) | 0.04 (46) | −4.6 (9.0) | −14.9 (10.2) | 2.3 (5.8) | −5.2 (11.7) |
| Median (Q1, Q3) weight change, kg | −11.1 (−17.3, –8.0) | −0.8 (−3.1, 2.1) | −3.1 (−8.0, 1.0) | −11.0 (−21.0, –8.0) | 1.3 (−3.0, 6.0) | −4.2 (−10.0, 3.0) |
*Includes maintaining baseline weight.
†This includes all patients who lost <5% of their baseline weight, maintained their baseline weight, or gained weight.
CPRD, Clinical Practice Research Datalink; GLP-1 RA, glucagon-like peptide-1 receptor agonist; T2DM, type 2 diabetes mellitus.